This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Frohlich, E. D. Search for Related Content PubMed PubMed Citation Articles by Frohlich, E. D.

(Hypertension. 2002;39:837.)
© 2002 American Heart Association, Inc.

In Memoriam

H. Mitchell Perry, Jr, MD

Edward D. Frohlich, MD

Ochsner Clinic Foundation New OrleansLouisiana

One of the leading workers in the hypertension field since the early days of the development of antihypertensive therapeutic agents was H. Mitchell Perry, Jr, MD. Not only was he totally committed to new therapeutic advances, but his investigative activities were also focused in the laboratory where he was deeply immersed in identifying the role of environmental substances that may participate in the pathogenesis of hypertension. In these studies he was a world authority on the role of such specific metallic ions as cadmium and lead.

"Mitch" Perry, as he was referred to by his many friends, spent his entire professional career in St. Louis at Washington University. Thus, after completing his undergraduate education at Swarthmore College, he entered that university, completing his medical education within 3 years. Then, following his training in internal medicine at Barnes Hospital and a stint in the US Army in Frankfurt, Germany, he returned to Washington University for further training in the basic sciences with the Coris at the time they received the Nobel Prize. After his training in biochemistry, he began his fellowship with Doctor Henry Schroeder. They were among the first to demonstrate the efficacy of hydralazine in controlling arterial pressure and in reversing the unrelenting course of malignant hypertension toward certain death. Mitch was one of the original members of the Council for High Blood Pressure Research, and he described, in his extensive studies of hydralazine, its ability to induce lupus erythematosis and its association with the slow-acetylator genotype in treated . . . [Full Text of this Article]